STAB RSI Chart
Trailing 12 Months
-100%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2022 | 2.5M | 3.3M | 3.7M | 0 |
2021 | 0 | 0 | 343.4K | 1.5M |
2020 | 1.1M | 857.8K | 631.8K | 262.9K |
2019 | 1.1M | 993.9K | 980.2K | 1.1M |
2018 | 1.6M | 1.8M | 1.8M | 1.1M |
2017 | 3.3M | 2.9M | 2.1M | 1.9M |
2016 | 2.9M | 3.2M | 3.8M | 3.5M |
2015 | 3.0M | 2.7M | 2.8M | 2.7M |
2014 | 8.5M | 7.4M | 6.2M | 3.7M |
2013 | 4.0M | 5.4M | 6.8M | 8.5M |
2012 | 7.2M | 6.9M | 3.4M | 3.6M |
2011 | 13.6M | 10.0M | 10.6M | 8.8M |
2010 | 0 | 14.7M | 15.0M | 15.3M |
2009 | 0 | 0 | 0 | 14.3M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Sep 28, 2021 | markvicka taunia | acquired | - | - | 100,000 | chief operating officer |
Sep 09, 2021 | barbarick steve k | acquired | - | - | 60,000 | - |
Sep 09, 2021 | saluck randy s. | acquired | - | - | 60,000 | - |
Sep 09, 2021 | verny lea | acquired | - | - | 60,000 | - |
Which funds bought or sold STAB recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
Mar 04, 2024 | TUCKER ASSET MANAGEMENT LLC | unchanged | - | 1.00 | 1.00 | -% |
Nov 21, 2022 | FourThought Financial, LLC | unchanged | - | - | - | -% |
Nov 03, 2022 | DOWLING & YAHNKE LLC | unchanged | - | -4,000 | 4,000 | -% |
Unveiling Statera Biopharma, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Statera Biopharma, Inc. News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 | 2017Q3 | 2017Q2 | 2017Q1 |
Revenue | -12.8% | 670 | 769 | 998 | 1,251 | 237 | - | 44.00 | 63.00 | 156 | 369 | 270 | 277 | 198 | 236 | 283 | 392 | 228 | 870 | 297 | 206 | 575 |
Gross Profit | -11.8% | 501 | 568 | 644 | 878 | 121 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses | -40.2% | 2,048 | 3,421 | 7,258 | 78,060 | 9,765 | 3,391 | 6,171 | 655 | 600 | 650 | 788 | 1,049 | 988 | 864 | 1,551 | 1,460 | 2,064 | 2,084 | 1,494 | 1,777 | 2,194 |
S&GA Expenses | -31.1% | 13.00 | 19.00 | 37.00 | 53.00 | 23.00 | -431 | - | 485 | 382 | 369 | 526 | 449 | 475 | 329 | 712 | 551 | 727 | 560 | 575 | 588 | 777 |
R&D Expenses | -76.3% | 231 | 974 | 3,242 | 5,555 | 3,435 | 623 | 4,383 | 170 | 218 | 281 | 262 | 600 | 513 | 534 | 839 | 909 | 1,336 | 1,524 | 919 | 1,188 | 1,417 |
Interest Expenses | - | - | - | 540 | 972 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income | 4.1% | -3,348 | -3,490 | -7,759 | -77,245 | -12,719 | -4,836 | -5,678 | -369 | -601 | -688 | -449 | -633 | -893 | -404 | -1,104 | -872 | -1,258 | -1,305 | -1,260 | -5,612 | -1,663 |
Net Income Margin | 19.9% | -24.91* | -31.11* | -44.01* | -68.49* | -24.92* | -43.69* | -11.62* | -2.46* | -2.22* | -2.39* | -2.43* | - | - | - | - | - | - | - | - | - | - |
Free Cashflow | -375.7% | -801 | -168 | -3,768 | -7,456 | -15,283 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 | 2017Q3 |
Assets | -5.9% | 12,749 | 13,542 | 13,510 | 21,170 | 98,036 | 13,829 | 14,700 | 1,035 | 3,231 | 4,079 | 1,865 | 2,037 | 2,229 | 3,086 | 3,780 | 4,534 | 5,698 | 7,056 | 8,370 | 9,629 | 10,872 |
Current Assets | -27.3% | 1,214 | 1,669 | 1,438 | 4,147 | 13,328 | 13,824 | 14,694 | 926 | 3,225 | 4,070 | 1,833 | 2,003 | 2,193 | 3,047 | 3,725 | 4,476 | 5,639 | 6,995 | 8,308 | 9,580 | 10,822 |
Cash Equivalents | -8.6% | 506 | 554 | 152 | 1,845 | 9,216 | 13,777 | 14,359 | 594 | 2,721 | 3,409 | 1,059 | 1,126 | 1,487 | 2,238 | 2,799 | 3,617 | 4,379 | 4,007 | 4,586 | 4,231 | 4,591 |
Net PPE | -42.3% | 106 | 184 | 202 | 202 | 119 | 5.00 | 6.00 | 9.00 | 6.00 | 9.00 | 12.00 | 16.00 | 17.00 | 20.00 | 24.00 | 28.00 | 25.00 | 28.00 | 32.00 | 19.00 | 18.00 |
Goodwill | 0% | 9,267 | 9,267 | 9,267 | 9,267 | 76,973 | 12,634 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Liabilities | 12.0% | 22,917 | 20,464 | 15,945 | 22,676 | 23,841 | 17,458 | 11,075 | 4,691 | 484 | 787 | 1,085 | 1,053 | 566 | 943 | 1,018 | 920 | 1,602 | 1,797 | 2,156 | 2,221 | 2,272 |
Current Liabilities | 13.0% | 22,231 | 19,670 | 15,073 | 11,245 | 10,187 | - | - | 4,621 | 484 | 787 | 1,085 | 1,053 | 566 | 940 | 1,011 | 912 | 1,593 | 1,797 | 2,156 | 2,213 | 2,272 |
Shareholder's Equity | - | - | - | - | - | 74,208 | 144,331 | 150,923 | 143,486 | 147,754 | 3,292 | 779 | 984 | 247 | 2,142 | 2,761 | 3,614 | 4,096 | 5,260 | 6,213 | 7,408 | 3,364 |
Retained Earnings | -2.4% | -144,075 | -140,700 | -137,200 | -129,482 | -52,300 | -170,301 | -169,642 | -27,762 | -168,409 | -167,663 | -167,294 | -166,705 | -165,998 | -165,548 | -164,931 | -164,058 | -163,626 | -162,522 | -161,671 | -160,446 | -159,277 |
Additional Paid-In Capital | 0.0% | 133,527 | 133,465 | 134,529 | 127,743 | 126,220 | 179,476 | 179,475 | 23,947 | 166,765 | 166,503 | 163,666 | 163,162 | 163,162 | 163,162 | 163,162 | 163,162 | 163,162 | 163,162 | 163,162 | 163,106 | 163,106 |
Shares Outstanding | 2.2% | 50,745 | 49,641 | 49,980 | 35,484 | 27,037 | 24,527 | 24,424 | 13,376 | 3,081 | 11,652 | 11,353 | 11,298 | 11,298 | - | - | - | - | - | - | - | - |
Minority Interest | 8.3% | 73.00 | 67.00 | 50.00 | 61.00 | 72.00 | 4,959 | 4,962 | - | 4,972 | 5,000 | 4,993 | 5,040 | 5,026 | 5,048 | 5,060 | 5,066 | 5,094 | 5,129 | 5,177 | 5,209 | 5,235 |
Float | - | - | - | - | - | - | 48,863 | - | - | - | 33,225 | - | - | - | 16,382 | - | - | - | 11,634 | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 | 2017Q3 |
Cashflow From Operations | -375.7% | -801 | -168 | -3,761 | -7,359 | -15,219 | -3,021 | -2,592 | 3,281 | -7,461 | -476 | -425 | -364 | -713 | -758 | -827 | -1,172 | -1,159 | -1,082 | -1,199 | -1,279 | -1,432 |
Share Based Compensation | 73.0% | -287 | -1,065 | 453 | 1,102 | 1,179 | 1,963 | 1,816 | 2,826 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cashflow From Investing | - | - | - | -6.45 | -96.91 | 13,045 | 520 | -4.68 | -3.02 | -49.86 | - | - | -1.76 | -31.74 | 190 | - | 406 | 1,548 | 512 | 1,501 | 920 | 2,094 |
Cashflow From Financing | 42.3% | 712 | 500 | -2,898 | 89.00 | 672 | 18,072 | 2,155 | -3,004 | 5,522 | 2,783 | 382 | - | - | - | - | - | - | - | 55.00 | - | - |
Buy Backs | - | - | - | 51.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Revenues: | ||||
Grants and contracts | $ 670,473 | $ 236,519 | $ 2,437,139 | $ 236,519 |
Cost of goods sold | 169,354 | 115,927 | 723,961 | 115,927 |
Gross profit | 501,119 | 120,592 | 1,713,178 | 120,592 |
Operating expenses: | ||||
Research and development | 230,604 | 3,434,977 | 4,446,535 | 6,274,936 |
Sales and marketing expense | 13,350 | 23,242 | 69,750 | 26,037 |
General and administrative | 1,803,607 | 6,306,323 | 8,210,391 | 14,981,086 |
Total operating expenses | 2,047,561 | 9,764,542 | 12,726,676 | 21,282,059 |
Loss from operations | (1,546,442) | (9,643,950) | (11,013,498) | (21,161,467) |
Other expense: | ||||
Interest and other expense | (1,810,473) | (3,089,301) | (3,593,897) | (3,463,572) |
Total other expense | (1,810,473) | (3,089,301) | (3,593,897) | (3,463,572) |
Income from discontinued operations, net of income taxes | 0 | (1) | 0 | (1) |
Net loss | (3,356,915) | (12,733,250) | (14,607,395) | (24,625,038) |
Net loss attributable to noncontrolling interests | 8,103 | 13,419 | 13,979 | 13,419 |
Net loss attributable to Statera Biopharma, Inc. | $ (3,348,812) | $ (12,719,831) | $ (14,593,416) | $ (24,611,619) |
Net loss attributable to common stockholders per share of common stock, basic and diluted (in dollars per share) | $ (0.07) | $ (0.47) | $ (0.32) | $ (0.86) |
Weighted average number of shares used in calculating net loss per share, basic and diluted (in shares) | 50,234,111 | 27,036,583 | 45,906,659 | 28,671,422 |
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) | Sep. 30, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 506,098 | $ 1,844,732 |
Short-term investments | 0 | 134,603 |
Accounts receivable | 183,383 | 216,183 |
Prepaid expenses | 97,515 | 981,895 |
Contract asset | 178,048 | 132,572 |
Other current assets | 248,457 | 837,358 |
Total current assets | 1,213,501 | 4,147,343 |
Non-current assets: | ||
Operating lease right-of-use assets | 914,226 | 964,331 |
Restricted cash | 0 | 5,000,000 |
Goodwill | 9,267,007 | 9,267,007 |
Intangible assets, net | 1,239,853 | 1,580,980 |
Property and equipment, net | 106,415 | 201,901 |
Total non-current assets | 11,527,501 | 17,014,219 |
Assets of discontinued operation | 8,123 | 8,123 |
Total assets | 12,749,125 | 21,169,685 |
Current liabilities: | ||
Accounts payable and accrued expenses | 14,442,069 | 5,715,956 |
Current portion of operating lease liabilities | 323,631 | 254,998 |
Deferred revenue | 386,929 | 373,468 |
Stock issuances due | 682,078 | 325,828 |
Notes payable | 6,396,486 | 4,575,000 |
Total current liabilities | 22,231,193 | 11,245,250 |
Operating lease liabilities, net of current portion | 686,140 | 806,140 |
Long-term debt | 0 | 10,625,000 |
Total long-term liabilities | 686,140 | 11,431,140 |
Liabilities of discontinued operation | 63 | 63 |
Total liabilities | 22,917,396 | 22,676,453 |
Stockholders’ equity (deficit): | ||
Preferred stock, $.005 par value; 1,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 0 shares issued and outstanding as of September 30, 2022 and December 31, 2021 | 0 | 0 |
Common stock, $.005 par value; 150,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 50,744,653 shares issued and outstanding as of September 30, 2022 and 35,484,106 shares issued and outstanding as of December 31, 2021 | 253,724 | 177,421 |
Additional paid-in capital | 133,526,843 | 127,743,333 |
Accumulated other comprehensive income (loss) | 53,695 | (6,651) |
Accumulated deficit | (144,075,557) | (129,482,141) |
Total Statera Biopharma, Inc. stockholders’ deficit | (10,241,295) | (1,568,038) |
Noncontrolling interest in stockholders’ equity | 73,024 | 61,270 |
Total stockholders’ deficit | (10,168,271) | (1,506,768) |
Total liabilities and stockholders’ deficit | $ 12,749,125 | $ 21,169,685 |